| 6.05 0.1 (1.68%) | 08-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.15 | 1-year : | 9.64 |
| Resists | First : | 6.98 | Second : | 8.26 |
| Pivot price | 5.71  |
|||
| Supports | First : | 4.9 | Second : | 4.08 |
| MAs | MA(5) : | 5.92 |
MA(20) : | 5.95 |
| MA(100) : | 7.95 |
MA(250) : | 9.26 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 68.7 |
D(3) : | 58 |
| RSI | RSI(14): 43.5 |
|||
| 52-week | High : | 15.71 | Low : | 4.9 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SPRY ] has closed below upper band by 21.3%. Bollinger Bands are 42.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.08 - 6.11 | 6.11 - 6.12 |
| Low: | 5.75 - 5.78 | 5.78 - 5.8 |
| Close: | 6.01 - 6.05 | 6.05 - 6.09 |
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Thu, 13 Aug 2026
Hennion & Walsh Asset Management Inc. Acquires Shares of 175,614 ARS Pharmaceuticals, Inc. $SPRY - marketbeat.com
Wed, 12 Aug 2026
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Wed, 12 Aug 2026
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earnings - Yahoo Finance
Wed, 12 Aug 2026
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 99 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 16.2 (%) |
| Held by Institutions | 95.5 (%) |
| Shares Short | 22,670 (K) |
| Shares Short P.Month | 23,090 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | -200 % |
| Operating Margin | -265.2 % |
| Return on Assets (ttm) | -41.2 % |
| Return on Equity (ttm) | -136.4 % |
| Qtrly Rev. Growth | 184.5 % |
| Gross Profit (p.s.) | 0.59 |
| Sales Per Share | 0.99 |
| EBITDA (p.s.) | -2.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -175 (M) |
| Levered Free Cash Flow | -98 (M) |
| PE Ratio | -3.03 |
| PEG Ratio | 0 |
| Price to Book value | 9.75 |
| Price to Sales | 6.06 |
| Price to Cash Flow | -3.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|